Rates of topoisomerase II-alpha and HER-2 gene amplification and expression in epithelial ovarian carcinoma

Gynecologic Oncology

Volumn 92, Issue 3, 2004, Pages 887-895

  Mano, M S ^a   Awada, A ^a   Di Leo, A ^a   Durbecq, V ^a   Paesmans, M ^a   Cardoso, F ^a   Larsimont, D ^a   Piccart, M ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

Chemotherapy; HER 2; Ovarian cancer; Topoisomerase II alpha

Indexed keywords

BIOLOGICAL MARKER; DNA TOPOISOMERASE (ATP HYDROLYSING);

ARTICLE; CANCER STAGING; CENTROMERE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE MARKER; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE EXPRESSION; GENE OVEREXPRESSION; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; ONCOGENE NEU; OVARY CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

EID: 1342300676     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ygyno.2003.12.010     Document Type: Article

References (45)

1. Boring C.et al. CA-A Cancer J. Clin. 44(1):1994;7-26.
2. McGuire W.P., Hoskins W.J., Brady M.F.et al. Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the Gynecologic Oncology Group). Semin. Oncol. 5:1996;40-47.
3. Piccart M.J., Bertelsen K., James K. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J. Natl. Cancer Inst. 92:2000;699-708.
4. Vermorken J.B., Kobierska A., Chevallier B.et al. A phase II study of high-dose epirubicin in ovarian cancer patients previously treated with cisplatin. EORTC Gynecological Cancer Cooperative Group. Ann. Oncol. 11:2000;1035-1040.
5. Rose P.G., Blessing J.A., Mayer A.R., Homesley H.D. Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study. J. Clin. Oncol. 16:1998;405-410.
6. Gordon A.N., Fleagle J.T., Guthrie D.et al. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J. Clin. Oncol. 19:2001;3312-3322.
7. The Ovarian Cancer Meta-Analysis Project. Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin, and cisplatin chemotherapy of ovarian carcinoma: a meta-analysis. J Clin Oncol 9 1668-1674.
8. du Bois A., Weber B., Pfisterer J.et al. Epirubicin/paclitaxel/ carboplatin (TEC) vs. paclitaxel/carboplatin (TC) in first-line treatment of ovarian cancer FIGO stages IIb-IV. Interim results of an AGO-GINECO-intergroup phase III trial. Proc. Am. Soc. Clin. Oncol. 20:2001;202a. [abstract 805].
9. Kristensen G., Vergote I., Stuart G.et al. First line treatment of ovarian cancer FIGO stages IIb-IV with paclitaxel/epirubicin/carboplatin (TEC) vs. paclitaxel/carboplatin (TC). Interim results of an NSGO-EORTC-NCIC CTG Gynecological Cancer Intergroup phase III trial. Proc. Am. Soc. Clin. Oncol. 21:2002;202a. [abstract 805].
10. Kellner U., Sehested M., Jensen P.et al. Culprit and victim - DNA topoisomerase II. Lancet Oncol. 3:2002;235-243.
11. Isola J.J.et al. Amplification of topoisomerase II alpha is strong predictor of response to epirubicin-based chemotherapy in HER-2/neu-positive metastatic breast cancer. Proc. San Antonio Breast Cancer Meeting. 64:2000 (December);31. (abstr. 21).
12. Di Leo A., Larsimont D., Gancberg D.et al. HER-2 and topoisomerase IIa as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide. Ann. Oncol. 12:2001;1081-1089.
13. Di Leo A., Gancberg D., Larsimont D. HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. Clin. Cancer Res. 8:2002;1107-1116.
14. Durbecq V., Di Leo A., Rouas G.et al. Correlation between topoisomerase II-alpha (TOPO-II) gene amplification and protein expression in HER-2 amplified breast cancer. Proc. Am. Soc. Cancer Res. 44:2003;937.
15. Cornarotti M., Capranico G., Bohm S.et al. Gene expression of DNA topoisomerases I, II alpha and II beta and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Int. J. Cancer. 67:1996;479-484.
16. Van der Zee A.G.J., de Vries E.G.E., Hollema H.et al. Molecular analysis of the topoisomerase II alpha gene and its expression in human ovarian cancer. Ann. Oncol. 5:1994;75-81.
17. Koshiyama M., Fujii H., Kinezaki M.et al. Correlation between Topo II alpha expression and chemosensitivity testing for Topo II-targeting drugs in gynaecological carcinomas. Anticancer Res. 21:2001;905-910.
18. Gotlieb W., Goldberg I., Weisz B.et al. Topoisomerase II immunostaining as a prognostic marker for survival in ovarian cancer. Gynecol. Oncol. 82:2001;99-104.
19. Withoff S., van der Zee A.G.J., Jong de S.et al. DNA topoisomerae II alpha and beta expression in human ovarian cancer. Br. J. Cancer. 79:1999;748-753.
20. Koshiyama M., Fujii H., Kinezaki M.et al. Immunohistochemical expression of topoisomerase II alpha (Topo IIalpha) and multidrug resistance-associated protein (MPR), plus chemosensitivity testing, as chemotherapeutic indices of ovarian and endometrial carcinomas. Anticancer Res. 21:2001;2925-2932.
21. Topoisomerase II-a amplification as potential predictive marker of complete response to anthracycline-based chemotherapy in locally advanced/metastatic breast cancer. Cardoso F., Durbecq V., Bernard-Marty C., Rouas G., Leroy J.-Y., Mano M., Giuliani R., Larsimont D., Jacobson K., Piccart M.J., Di Leo A. San Antonio Breast Cancer Conference. 2002;. [abstract 218].
22. Afify A.M., Werness B.A., Mark H.F.et al. HER-2. /neu oncogene amplification in stage I and stage III ovarian papillary serous carcinoma Exp. Mol. Pathol. 66:1999;163-169.
23. Young S.R., Wei-Hua L., Jo-Ann B., Smith S. ERB2 and chromosome 17 centromere studies of ovarian cancer by fluorescence in situ hybridization. Genes Chromosomes Cancer. 16:1996;130-137.
24. Fajac A., Bernard J., Lhomme C.et al. c-erb2 gene amplification and protein expression in ovarian epithelial tumors: evaluation of their respective prognostic significance by multivariate analysis. Int. J. Cancer (Pred. Oncol.). 64:1995;146-151.
25. Bookman M., Darcy K., Clarke-Pearson D.et al. Evaluation of monoclonal humanized anti-HER2 antibody trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. J. Clin. Oncol. 21:2003;283-290.
26. Durbecq V., Di Leo A., Cardoso F.et al. Comparison of topoisomerase-IIa gene status between primary breast cancer and corresponding distant metastatic sites. Breast Cancer Res. Treat. 77(3):2003;199-204.
27. Gancberg D., Di Leo A., Cardoso F.et al. Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites. Ann. Oncol. 13:2002;1036-1043.
28. Tanner M., Järvinen P., Isola J.et al. Amplification of HER-2/neu and topoisomerase II-a in primary and metastatic breast cancer. Cancer Res. 61:2001;5345-5348.
29. Slamon D.J., Godephin W., Jones L.A.et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 244:1989;707-712.
30. Zhuag X., Silva E., Gershenson D.et al. Amplification and re-arrangements of c-erb protooncogenes in cancer of human female genital tract. Oncogene. 4:1989;985-989.
31. Kury F.D., Schneeberger C., Sliutz G.et al. Determination of HER2/neu amplification and expression in tumour tissue and cultured cells using a single phenol free method for nucleic acid isolation. Oncogene. 5:1990;1403-1408.
32. Zheng J., Robinson W.R., Ehlen T.et al. Distinction of low grade from high grade human ovarian carcinomas as the basis of losses of heterozygosity in chromosomes 3, 6 and 11 and HER2/neu gene amplification. Cancer Res. 51:1991;4045-4051.
33. Fukushi Y., Sato S., Yokoyhama Y.et al. Detection of numerical aberration in chromosome 17 and c-erbB2 gene amplification in epithelial ovarian cancer using recently established dual color FISH. Eur. J. Gynaecol. Oncol. 22:2001;23-25.
34. Ross J.S., Yang F., Kallakury B.V.S.et al. HER-2/neu oncogene amplification by fluorescence in situ hybridization in epithelial tumors of the ovary. Am. J. Clin. Pathol. 11:1999;311-316.
35. Seki A., Yoshinouchi M., Seki N.et al. Detection of c-erbB-2 and FGF-3(INT-2) gene amplification in epithelial ovarian cancer. Int. J. Oncol. 17:2000;103-106.
36. Yang H., Zhang G., Xu K.et al. C-erbB-2 gene amplification in human primary epithelial ovarian cancer and its clinical significance. Zhonghua Zhongliu Zazhi. 20:1998;367ci-370ci.
37. Meden H., Kuhn W. Overexpression of the oncogene c-erbB-2 (HER-2/neu) in ovarian cancer: a new prognostic factor. Eur. J. Obstet. Gynecol. Reprod. Biol. 71:1997;173-179.
38. Hellstrom I., Goodman G., Pullman J.et al. Overexpression of HER-2 in ovarian carcinomas. Cancer Res. 61:2001;2420-2423.
39. Leng J., Lang J., Shen K., Guo L. Overexpression of p53, EGFR, c-erbB2 and c-erbB3 in endometrioid carcinoma of the ovary. Chin. Med. Sci. J. 12:1997;67-70.
40. Anreder M.B., Freeman S.M., Merogi A.et al. P53, c-erbB2, and PCNA status in benign, proliferative and malignant ovarian surface epithelial neoplasms: a study of 75 cases. Arch. Pathol. Lab. Med. 123:1999;310-316.
41. Halperin R., Zehavis S., Hadas E.et al. Immunohistochemical comparison of primary peritonial and primary ovarian serous papillary carcinoma. Int. J. Gynecol. Pathol. 20:2001;341-345.
42. Skirnisdottir I., Sorbe B., Seidal T. The growth factor receptors HER-2/neu and EGFR, their relationship and their effects on the prognosis in early stage (FIGO I-II) epithelial ovarian carcinoma. Int. J. Gynecol. Cancer. 11:2001;119-129.
43. Giaccone G., Gazdar A.F., Beck H.et al. Multidrug sensitivity phenotype of human lung cancer cell associated with topoisomerase II expression. Cancer Res. 52:1992;1666-1674.
44. Walter H., Gotlieb W., Goldberg I.et al. Topoisomerase II immunostaining as a prognostic marker for survival in ovarian cancer. Gynecol. Oncol. 82:2001;99-104.
45. Costa M.J., Hansel C.L., Holden J.A., Guinee D. Jr. Topoisomerase II alpha: prognostic predictor and cell cycle marker in surface epithelial neoplasms of the ovary and peritonium. Int. J. Gynecol. Pathol. 19:2000;248-257.